Icam1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Intercellular Adhesion Molecule 1 (ICAM1) is a 532-amino acid type I transmembrane glycoprotein that serves as a critical mediator of leukocyte adhesion, neuroinflammation, and blood-brain barrier (BBB) dysfunction in neurodegenerative diseases[1]. ICAM1 is expressed on endothelial cells, epithelial cells, fibroblasts, and immune cells, with its expression dramatically upregulated by proinflammatory cytokines[2].
| Attribute | Value |
|---|---|
| Protein Name | Intercellular Adhesion Molecule 1 |
| Gene Symbol | ICAM1 |
| Protein Length | 532 amino acids |
| Molecular Weight | ~90 kDa (unglycosylated); 110-120 kDa (glycosylated) |
| UniProt ID | P05362 |
| PDB Structures | 1IC1, 1IAQ, 1P53, 2AYZ |
| Cellular Location | Plasma membrane (type I transmembrane); also secreted as soluble form |
| Protein Family | Immunoglobulin superfamily (IgSF) |
The ICAM1 protein contains four distinct structural domains[3]:
ICAM1 serves as the primary ligand for leukocyte integrins[5]:
| Integrin | Alternative Name | Dissociation Constant (Kd) | Function |
|---|---|---|---|
| ITGAL/CD11a | LFA-1 | ~100 nM | Primary T cell receptor |
| ITGAM/CD11b | Mac-1 | ~500 nM | Monocyte/neutrophil receptor |
| ITGAX/CD11c | αXβ2 | ~1 μM | Dendritic cell receptor |
| ITGAM/CD11d | αDβ2 | ~500 nM | Activated macrophage receptor |
The D1 Ig-like domain contains the primary integrin binding site, specifically the "ADMIDAS" and "MIDAS" metal ion-dependent adhesion sites[4:1].
ICAM1 is heavily N-glycosylated with complex-type oligosaccharides at multiple asparagine residues[7]:
The cytoplasmic tail is phosphorylated on serine and threonine residues[8]:
Alternative splicing and proteolytic cleavage produce soluble forms[9]:
Several crystal structures reveal the molecular details[4:2]:
The five Ig-like domains are connected by flexible linkers, allowing the protein to adopt multiple conformations and engage multiple ligands simultaneously[10].
ICAM1 contributes to AD pathogenesis through multiple mechanisms[11][12]:
In PD, ICAM1 mediates neuroinflammation[18][19]:
ICAM1 is crucial for immune cell entry into the CNS[24]:
ICAM1 is elevated in ALS and contributes to inflammation[28]:
ICAM1 mediates post-injury neuroinflammation[32][33]:
| Strategy | Agent | Development Status | Notes |
|---|---|---|---|
| LFA-1 Antagonists | Lifitegrast (Efalizumab withdrawn) | Approved (dry eye) | Blocks ICAM1-LFA-1 |
| Small Molecules | Various inhibitors | Preclinical | Targeting protein-protein interaction |
| Antibodies | Anti-ICAM1 monoclonal | Research | Blocking antibodies |
| Gene Therapy | siRNA/shRNA | Preclinical | Reducing ICAM1 expression |
| Natural Compounds | Curcumin, resveratrol | Preclinical | NF-κB-mediated downregulation |
The study of Icam1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Springer TA (1994). Nature. 1994. ↩︎
Hynes RO (1992). Cell. 1992. ↩︎
Zlokovic BV (2008). Neurobiol Dis. 2008. ↩︎
Chiu JJ, et al. (2008). Arterioscler Thromb Vasc Biol. 2008. ↩︎